Biosergen publishes interim report for third quarter 2023
Thursday, November 30, 2023: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q3 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | July-Sep | July-Sep | Jan-Sept | Jan-Sep | Jan-Dec |
| Profit/loss | |||||
| Other income | 292 | 493 | 8.063 | 3.219 | 5.183 |
| Profit/loss before depreciation (EBITDA | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Operating profit/loss befor net financials | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Net financials | 27 | 16 | 36 | 22 | 81 |
| Netprofit/loss for the period | -7.510 | -14.499 | -20.568 | -27.474 | -34.048 |
| Earnings per share (SEK) | -0,15 | -0,51 | -0,48 | -0,97 | -1,09 |
Highlights during Q3 2023
- September 25, Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections.
- August 28, Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million.
- August 16, Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11).
Highlights after the period
- Abstract presented at the 11th Trends in Medical Mycology publicly available
The Financial report can be found on our website: https://biosergen.net/investors/filings